-
Calicheamicin
- names:
Calicheamicin
- CAS号:
108212-75-5
MDL Number: - MF(分子式): C55H74IN3O21S4 MW(分子量): 1368.35
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|---|---|---|---|---|---|---|---|
| YZM000901-5mg | 5mg | 98.44% | ¥ 11475.00 | ¥ 11475.00 | 2-3天 | ¥ 0.00 | ||
| YZM000901-1mg | 1mg | 98.44% | ¥ 5200.00 | ¥ 5200.00 | 2-3天 | ¥ 0.00 |
| 中文别名 | |
| 英文别名 | Calicheamicin |
| CAS号 | 108212-75-5 |
| Inchi | |
| InchiKey | |
| 分子式 Formula | C55H74IN3O21S4 |
| 分子量 Molecular Weight | 1368.35 |
| 溶解度Solubility | 生物体外In Vitro:DMSO溶解度≥ 100 mg/mL(73.08 mM)H2O< 0.1 mg/mL(insoluble)*"≥" means soluble可溶, but saturation unknown溶解度未知. |
| 性状 | |
| 储藏条件 Storage conditions | 粉末Powder: -20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月 |
| 产品说明 | |
| Introduction | Calicheamicin, an antitumor antibiotic, is a cytotoxic agent that causes doubletrand DNA breaks. Calicheamicin is a DNA synthesis inhibitor. |
| Application1 | |
| Application2 | |
| Application3 |
Calicheamicin, an antitumor antibiotic, is a cytotoxic agent that causes double-strand DNA breaks. Calicheamicin is a DNA synthesis inhibitor.
【1】.Damelin M, et al. Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions. Clin Cancer Res. 2015 Sep 15;21(18):4165-73
【2】.de Vries JF, et al. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia. 2012 Feb;26(2):255-64
【3】.Takeshita A, et al. CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells. Leukemia. 2009 Jul;23(7):1329-36.
【2】.de Vries JF, et al. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia. 2012 Feb;26(2):255-64
【3】.Takeshita A, et al. CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells. Leukemia. 2009 Jul;23(7):1329-36.
对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
抱歉,暂无数据!


购物车 


